EBC-46 Trial Adverse Event Profiles: Published Data on Tolerability Across Patient Cohorts
A neutral look at adverse events reported in published Phase I and Phase II EBC-46 trials, including injection-site reactions and what the overall tolerability picture shows.
Tolerability is a routine part of any early-phase clinical readout, and the tigilanol tiglate (EBC-46) human programme has now produced enough published material to describe adverse event (AE) patterns in reasonable detail. This article summarises what the public record shows, staying strictly within data from peer-reviewed publications and QBiotics’ publicly disclosed trial summaries.
Injection-site reactions dominate the AE profile
Across the first-in-human and subsequent studies of intratumoral tigilanol tiglate, the most common treatment-related AEs are localised to the injection site. These include pain, erythema, swelling, haemorrhage, and formation of an eschar that progresses to a healing wound. Published Phase I human safety data characterises these events as expected pharmacodynamic effects rather than unexpected toxicities — they reflect the mechanism of action rather than off-target harm.
For full context on the dose-escalation design that produced these observations, see our earlier summary of the EBC-46 Phase I Dose Escalation readout.
Systemic adverse events are rare
Because tigilanol tiglate is administered intratumorally and has limited systemic exposure, classical chemotherapy-style systemic AEs are comparatively uncommon. Nausea, fatigue, and transient lymphadenopathy have been reported at low frequency in Phase I, generally Grade 1–2 on the CTCAE v5 grading scale. Serious (Grade 3+) systemic events attributable to the drug have been infrequent in the published cohorts.
Wound healing as part of the AE profile
Because tigilanol tiglate produces a localised wound, wound care and healing trajectory become part of the tolerability picture. The published wound healing timelines show median closure within several weeks, with occasional slower healing in patients with comorbidities affecting tissue repair. This is consistent with the long-term follow-up analyses that have tracked treated sites post-trial.
Tolerability varies by tumour type and location
Across the trial portfolio, AE profile has varied with tumour location (superficial vs. deeper), histology, and patient performance status. Superficial cutaneous tumours have generally shown a more predictable wound-healing course than mucosal or deeper soft-tissue targets. This mirrors the veterinary experience where Stelfonta was approved for canine mast cell tumours — a tumour type anatomically accessible and well-characterised.
Pre-medication and supportive care
Published trial protocols describe the use of pre-medication strategies — notably corticosteroids and non-steroidal anti-inflammatory agents — intended to reduce the intensity of acute inflammatory responses in the hours after injection. Post-procedure wound care follows standard dermatologic or surgical practice, including dressing changes and monitoring for infection. These are routine aspects of managing any intratumorally administered agent that produces a local wound, and they are reported in the QBiotics Phase II combined analysis alongside efficacy data.
Comparison with the veterinary record
The veterinary programme for tigilanol tiglate, now commercialised as Stelfonta, has the longest real-world safety record. Published post-market safety summaries for canine mast cell tumours report a similar pattern: predictable local AEs, predominantly Grade 1–2 on veterinary adaptations of CTCAE, with systemic events uncommon. While species differences prevent a one-to-one translation, the consistency across species is part of why regulators have viewed the compound’s safety envelope favourably.
What the overall safety picture shows
Taken together, the published safety data characterises tigilanol tiglate as producing predictable, on-mechanism local AEs with limited systemic toxicity. This profile is one reason regulators have been willing to authorise expanded indications in veterinary medicine and continue to engage with QBiotics on human development pathways.
Scope and supplement context
Readers should note carefully that this safety data applies to pharmaceutical-grade tigilanol tiglate administered by a clinician in a clinical trial. It does not apply to oral blushwood berry extract supplements, which are a distinct product category with no therapeutic claims. Consumer products such as Blushwood Health blushwood berry extract are dietary supplements, not intended to diagnose, treat, cure or prevent any disease, and should not be interpreted through the lens of pharmaceutical trial data.
Related Articles
Related clinical reading: Patient-Reported Outcomes in Tigilanol Tiglate Trials and EBC-46 Tumour Response by Histology.
